This article is more than 5 years old. Information may no longer be current.
The Advent of Biosimilars: Experts Debate Concepts, Concerns
The arrival of biosimilar therapies was the topic that dominated the discussion at the Advances in Inflammatory Bowel Diseases meeting in Orlando, Fla., in December. As gastroenterologists await the arrival of biosimilars to the US market, uncertainty persists regarding how these new agents will impact patient care.
“Biosimilars are going to be coming to the US, and ... our field is not very familiar with these,” Stephen B. Hanauer, MD, AGAF, FACG, professor of medicine at Northwestern University Feinberg School of Medicine in Chicago, and co-chair of AIBD 2015, said during an interview at the meeting.
Speaking with Hanauer and other experts, Healio Gastroenterology’s Cover Story this month provides an in-depth examination of the issues surrounding biosimilar therapies, including their development and abbreviated regulatory pathways, potential cost-savings and concerns regarding immunogenicity.
Please visit our AIBD 2015 Resource Center at Healio.com/GI to see additional video perspectives on biosimilars from experts interviewed for this article.
Additionally, our By the Numbers feature recaps the top seven IBD studies presented at ACG 2015 in Honolulu, and we also bring you the most highly visited articles on Healio.com from UEG in Barcelona, Spain.
As always, we look forward to receiving input on our peer-tested content from our readers, as well as to a new year of shaping the pages of Healio Gastroenterology around your vital feedback.
The Editors Healio Gastroenterology gastroenterology@slackinc.com